The human cost of high insulin prices

  • The global insulin market is dominated by three companies: Eli Lilly, the French company Sanofi and the Danish firm Novo Nordisk.
  • In the past decade alone, U.S. insulin list prices have tripled, according to an analysis of data from IBM Watson Health
  • According to IBM Watson Health data, Sanofi’s popular insulin brand Lantus was $35 a vial when it was introduced in 2001; it’s now $270. Novo Nordisk’s Novolog was priced at $40 in 2001, and as of July 2018, it’s $289.
  • Stories of people rationing insulin and dying as a result continue to appear in the media.
Continue reading